Ovarian cancer vaccine clinical trial begins enrollment

Ovarian cancer is a steady, silent killer--its diagnosis is easy to miss and there are few options to prevent recurrence after treatment. Australian biotech company Prima BioMed's vaccine, known as Cvac, is in clinical development, and Sarasota Memorial Hospital in the U.S. will be the first site in the world approved to begin enrolling patients in the company's international Phase II trial. The ovarian cancer vaccine is a personalized treatment made from the patient's dendritic cells (white blood cells) and the protein mucin-1. Cvac is designed to prevent recurrence after surgery and chemotherapy in newly diagnosed women. Press release

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.